
    
      Data were collected on the efficacy and safety of neoadjuvant therapy in patients receiving
      albumin-binding taxol regimens,Subgroup analysis was performed for different treatment
      regimens, dosages, molecular subtypes and tumor stages,To further screen the dominant
      population and the chemotherapy regimen with clinical benefit of albumin paclitaxel, so as to
      provide evidence-based medical evidence for breast cancer neoadjuvant clinical diagnosis and
      treatment.
    
  